Treatment outcomes for Mycobacterium avium complex: A systematic review and meta-analysis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 3, 2014, Pages 347-358

  Xu, H B ^a   Jiang, R H ^a   Li, L ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MACROLIDE; MINOCYCLINE; OFLOXACIN; QUINOLONE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BLOOD CULTURE; DRUG EFFICACY; FOLLOW UP; HUMAN; META ANALYSIS; MORTALITY; MYCOBACTERIUM INTRACELLULARE AVIUM; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SPUTUM CULTURE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDITY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; HIV INFECTIONS; HUMANS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; TREATMENT OUTCOME;

EID: 84896702764     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1962-1     Document Type: Article

References (40)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367-416
2. Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, Fauville-Dufaux M, Feldman K, Havelkova M, Katila ML, Köksalan K, Pereira MF, Rodrigues F, Pfyffer GE, Portaels F, Urgell JR, Rüsch-Gerdes S, Tortoli E, Vincent V, Watt B; Spanish Group for Non-Tuberculosis Mycobacteria (2004) Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 8:1186-1193
3. Henry MT, Inamdar L, O'Riordain D, Schweiger M, Watson JP (2004) Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J 23:741-746
4. Simons S, van Ingen J, Hsueh PR, van Hung N, Dekhuijzen PN, Boeree MJ, van Soolingen D (2011) Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 17:343-349
5. Horsburgh CR Jr (1996) Epidemiology of Mycobacterium avium complex. In: Korvick JA, Benson CA (eds) Mycobacterium avium complex infection: progress in research and treatment. Marcel Dekker, New York, pp 1-22
6. Wang HX, Yue J, Han M, Yang JH, Gao RL, Jing LJ, Yang SS, Zhao YL (2010) Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008. Chin Med J 123:184-187
7. Griffith DE (1999) Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Drug Saf 21:137-152
8. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354:1896-1900
9. American Thoracic Society (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 156:S1-S25
10. Gelman A, Carlin JB, Stern HS, Rubin DB (2003) Bayesian data analysis. CRC Press, Boca Raton
11. Brooks SP, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7:434-455
12. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
13. Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR (1994) Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 121:905-911
14. Research Committee of the British Thoracic Society (2001) First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 56:167-172
15. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP (1995) Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest 107:1035-1040
16. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, Fong IW, Gill MJ, Rachlis AR, Lalonde RG, Fanning MM, Tsoukas CM (1996) A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 335:377-383
17. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, Benson CA, Meek K, Siepman N, Craft JC (1997) Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 11:311-317
18. Dautzenberg B, Truffot-Pernot C, Hazebroucq J, Legris S, Guérin C, Begelman C, Guermonprez G, Fievet MH, Chastang C, Grosset J (1997) A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections. Infection 25:16-21
19. Dubé MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, Dezfuli MG, Bozzette SA, Bartok AE, Leedom JM, Tilles JG, McCutchan JA (1997) A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. J Infect Dis 176:1225-1232
20. Roussel G, Igual J (1998) Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. Int J Tuberc Lung Dis 2:462-470
21. Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L (1998) Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 27:1278-1285
22. Cohn DL, Fisher EJ, Peng GT, Hodges JS, Chesnut J, Child CC, Franchino B, Gibert CL, El-Sadr W, Hafner R, Korvick J, Ropka M, Heifets L, Clotfelter J, Munroe D, Horsburgh CR Jr (1999) A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 29:125-133
23. Gordin FM, Sullam PM, Shafran SD, Cohn DL, Wynne B, Paxton L, Perry K, Horsburgh CR Jr (1999) A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 28:1080-1085
24. Fournier S, Burguière AM, Flahault A, Vincent V, Treilhou MP, Eliaszewicz M (1999) Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. Eur J Clin Microbiol Infect Dis 18:16-22
25. Koletar SL, Berry AJ, Cynamon MH, Jacobson J, Currier JS, MacGregor RR, Dunne MW, Williams DJ (1999) Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. Antimicrob Agents Chemother 43:2869-2872
26. Roger PM, Carles M, Agussol-Foin I, Pandiani L, Keïta-Perse O, Mondain V, De Salvador F, Dellamonica P (1999) Efficacy and safety of an intravenous induction therapy for treatment of disseminated Mycobacterium avium complex infection in AIDS patients: a pilot study. J Antimicrob Chemother 44:129-131
27. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F (1999) Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 160:866-872
28. Dunne M, Fessel J, Kumar P, Dickenson G, Keiser P, Boulos M, Mogyros M, White AC Jr, Cahn P, O'Connor M, Lewi D, Green S, Tilles J, Hicks C, Bissett J, Schneider MM, Benner R (2000) A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 31:1245-1252
29. Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr (2000) Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to mycobacterium avium complex. Clin Infect Dis 30:288-292
30. Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Inderlied CB, Flexner C, Neidig J, Chaisson R, Notario GF, Hafner R; AIDS Clinical Trials Group 223 Protocol Team (2003) A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Infect Dis 37:1234-1243
31. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP (2008) Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 63:627-634
32. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A (2006) Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 173:1283-1289
33. Kobashi Y, Matsushima T, Oka M (2007) A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 101:130-138
34. Jacobson MA, Yajko D, Northfelt D, Charlebois E, Gary D, Brosgart C, Sanders CA, Hadley WK (1993) Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis 168:112-119
35. Kemper CA, Havlir D, Haghighat D, Dubé M, Bartok AE, Sison JP, Yao YZ, Yangco B, Leedom JM, Tilles JG, Allen McCutchan J, Deresinski SC (1994) The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 170:157-164
36. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT (1996) Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 153:1766-1772
37. Ahn CH, Ahn SS, Anderson RA, Murphy DT, Mammo A (1986) A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 134:438-441
38. Kemper CA, Meng TC, Nussbaum J, Chiu J, Feigal DF, Bartok AE, Leedom JM, Tilles JG, Deresinski SC, McCutchan JA (1992) Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. Ann Intern Med 116:466-472
39. Dautzenberg B, Castellani P, Pellegrin JL, Vittecoq D, Truffot-Pernot C, Pirotta N, Sassella D (1996) Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Antimicrob Agents Chemother 40:1722-1725
40. Dautzenberg B, Olliaro P, Ruf B, Esposito R, Opravil M, Hoy JF, Rozenbaum W, Carosi GP, Micoud M, L'Age M, Pirotta N, Sassella D (1996) Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS. Clin Infect Dis 22:705-708